Related Experiment Videos
[Myelography with amipaque in infants and children (author's transl)]
Der Radiologe
|November 1, 1981
Abstract:
The non-ionic water-soluble contrast medium Amipaque (metrizamide) shows a lowered neurotoxicity, and therefore it may be used in the entire spinal canal. The better visibility of fine structures compared with oily and gaseous contrast media allows an excellent diagnostic approach to all spinal affections. Our technique of myelography is described and typical examples are given.
Insights
Amipaque (metrizamide), a non-ionic contrast agent, offers reduced neurotoxicity for safe spinal canal imaging. Its superior visualization aids in diagnosing spinal conditions effectively.
Area of Science:
- Radiology
- Neurology
- Medical Imaging
Background:
- Traditional contrast media like oily and gaseous agents have limitations in visualizing fine spinal structures.
- Neurotoxicity associated with some contrast agents restricts their application in spinal procedures.
Purpose of the Study:
- To evaluate the utility of Amipaque (metrizamide) as a non-ionic, water-soluble contrast medium for spinal canal imaging.
- To demonstrate the diagnostic advantages of Amipaque over conventional contrast media for spinal affections.
Main Methods:
- Myelography technique utilizing Amipaque (metrizamide) is described.
- Case examples illustrating the application and diagnostic yield of the technique are presented.
Main Results:
- Amipaque exhibits lower neurotoxicity, enabling its use throughout the entire spinal canal.
- Enhanced visibility of fine spinal structures is achieved compared to oily and gaseous contrast media.
Conclusions:
- Amipaque (metrizamide) is a safe and effective contrast agent for comprehensive spinal canal myelography.
- The improved visualization provided by Amipaque facilitates superior diagnostic accuracy for various spinal conditions.